Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

NCT07033585 is registered in ClinicalTrials.gov with Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair as lead sponsor.

NCT NCT07033585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07033585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
June 15, 2026
Completion date
November 28, 2026
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes